XLO News and Press, Xilio Therapeutics Inc. From 04/07/22

WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Marty Huber, M.D., president of research and development and chief medi...

The following slide deck was published by Xilio Therapeutics, Inc. in conjunction with this event. For further details see: Xilio Therapeutics (XLO) Investor Presentation - Slideshow

Xilio Therapeutics press release (NASDAQ:XLO): Q4 GAAP EPS of -$0.98 misses by $0.06. Cash and cash equivalents were $198.1 million as of December 31, 2021, compared to $19.2 million as of December 31, 2020.  Xilio continues to believe that its existing cash and cash equivalents will be ...

Initial Phase 1 Data Readouts from Clinical Trials of XTX101 and XTX202 Anticipated in 2022 On Track with Plans to Submit IND for XTX301 in Second Half of 2022 Continue to Anticipate Cash Runway into 2024 with $198.1 Million in Cash and Cash Equivalents at Year-End 2021 ...

WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will p...

WALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm. D., president and chief executive officer, and M...

WALTHAM, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the first patient has been dosed in the company ...

WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Yuan Xu, Ph.D., to its board of directors. “Y...

Recording the fourth intra-day decline in a row, the shares of the recently IPO’ed biotech company Xilio Therapeutics (XLO -22.1%) remain at the lowest level since the company’s public debut about one and a half months ago. Approximately 335.0K shares have changed hands so far, ...

Xilio Therapeutics (NASDAQ:XLO): Q3 GAAP EPS of -$21.27. Press Release Cash and cash equivalents were $99.8 million as of September 30, 2021, compared to $19.2 million as of December 31, 2020. Cash and cash equivalents as of September 30, 2021 do not include $116.3 million in estimated net pr...